DOACs in elective electrical cardioversion 31 Table 2. Study outcomes <60 days after ECV Total n=1,431 VKA group n=943 DOAC group n=488 p-value Primary efficacy endpoint Stroke, TIA and SEE 8 (0.56) 6 (0.64) 2 (0.41) 0.72 Primary safety endpoint Major bleeding 3 (0.21) 1 (0.11) 2 (0.41) 0.27 Secondary endpoints All-cause death 8 (0.56) 5 (0.53) 3 (0.61) 1.00 Stroke 3 (0.21) 2 (0.21) 1 (0.20) 1.00 TIA 5 (0.35) 4 (0.42) 1 (0.20) 0.67 SEE - - - - Stroke and SEE 3 (0.21) 2 (0.21) 1 (0.20) 1.00 All data depicted as n (%) unless stated otherwise. DOAC = direct-acting oral anticoagulant; ECV = electrical cardioversion; SEE = systemic embolic event; TIA = transient ischemic attack; VKA = vitamin K antagonist. Figure legends Abbreviations: DOAC = direct oral anticoagulant, ECV= electrical cardioversion, INR= International Normalized Ratio, LAA= left atrial appendage.
RkJQdWJsaXNoZXIy MTk4NDMw